AbbVie breaks ground on new $195-M API manufacturing facility 
AbbVie has announced the start of construction of a new $195-million active pharmaceutical ingredient (API) manufacturing plant in North Chicago, Illinois. The facility was announced in August 2025. 

When completed, AbbVie’s new North Chicago API facility will expand the company’s chemical synthesis capabilities and enable AbbVie to bring API production for select products from Europe and Asia to the US. The facility is projected to be fully operational in 2027. 

In addition, late last month (September 2025), AbbVie announced the start of construction of a $70-million expansion at the AbbVie Bioresearch Center in Worcester, Massachusetts, which serves as a center of excellence for biologics research and development and manufacturing. The project will further expand AbbVie’s US-based domestic biologics manufacturing capacity to meet increased global demand and support US production of current and future oncology and immunology medicines. The expansion is part of the company’s previously announced commitment to invest more than $10 billion of capital in the US to broadly support innovation and expand critical biologics manufacturing capabilities and capacity. 

Source: AbbVie 

Lupin investing $250 M in new manufacturing facility in Florida 
Lupin, a Mumbai, India-based bio/pharmaceutical company, has announced plans for a new $250-million pharmaceutical manufacturing plant in Coral Springs, Florida.  

The $250-million investment includes research & development, infrastructure, and capital expenditures over a five-year period. The new site will have the capacity to accommodate the production of more than 25 respiratory medicines, including albuterol inhalers. Lupin acquired more than five acres of land for the 70,000-square-foot facility. 

The new facility will build on the company’s existing presence in Florida, which is home to Lupin’s US headquarters in Naples and its Advanced Inhalation Research Center. Lupin also operates another US drug-product manufacturing facility in Somerset, New Jersey. It currently has 15 manufacturing sites globally (12 in India and one each in Mexico, Brazil, and the US).  

Source: Lupin